Literature DB >> 8842127

Plasmodium vivax infections in chimpanzees for sporozoite challenge studies in monkeys.

J S Sullivan, C L Morris, H M McClure, E Strobert, B B Richardson, G G Galland, I F Goldman, W E Collins.   

Abstract

The development and testing of vaccines directed against Plasmodium vivax has relied on Saimiri and Aotus monkeys as the animal test system and on chimpanzees to provide infective gametocytes to produce sporozoites for monkey challenge studies and vaccine development. One sporozoite-induced and 29 blood-induced infections with the Salvador I strain of P. vivax were studied in splenectomized chimpanzees. Eighteen primary infections with P. vivax resulted in maximum parasite counts ranging from 1,519 to 81,810/ microliters (median 29,100/microliters). Twelve infections induced in animals previously infected with the homologous or heterologous strains of P. vivax had maximum parasite counts ranging from 155 to 14,136/microliters (median 1,736/microliters). A total of 202 of 237 lots containing a total of 293,175 Anopheles freeborni, An. stephensi, An. gambiae, An. dirus, An. quadrimaculatus, and An. maculatus mosquitoes were infected by membrane feeding on gametocytes from chimpanzees. Despite lower levels of parasitemia during secondary (reinfection) parasitemia, 66 of 70 lots of mosquitoes (94.3%) were infected. Based on the mean number of oocysts per positive mosquito gut, An. freeborni was more heavily infected than An. stephensi; An. stephensi was more heavily infected than An. gambiae; there was no significant difference between An. stephensi and An. dirus. Sporozoites from An. stephensi, An. gambiae, An. dirus, and An. freeborni infected with the Salvador I strain of P. vivax produced in chimpanzees were used to infect 193 Saimiri and six Aotus monkeys as well as one chimpanzee.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842127     DOI: 10.4269/ajtmh.1996.55.344

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Authors:  H Hisaeda; A W Stowers; T Tsuboi; W E Collins; J S Sattabongkot; N Suwanabun; M Torii; D C Kaslow
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Specificity of the IgG antibody response to Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale MSP119 subunit proteins in multiplexed serologic assays.

Authors:  Jeffrey W Priest; Mateusz M Plucinski; Curtis S Huber; Eric Rogier; Bunsoth Mao; Christopher J Gregory; Baltazar Candrinho; James Colborn; John W Barnwell
Journal:  Malar J       Date:  2018-11-09       Impact factor: 2.979

Review 3.  Parasite-Host Interaction and Pathophysiology Studies of the Human Relapsing Malarias Plasmodium vivax and Plasmodium ovale Infections in Non-Human Primates.

Authors:  Erica M Pasini; Clemens H M Kocken
Journal:  Front Cell Infect Microbiol       Date:  2021-02-17       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.